Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial - Treat 2b - Of Tregalizumab In Rheumatoid Arthritis

Dokoupilova, E (author)

Jeka, S (author)

Vencovsky, J (author)

show more...

Badurski, J (author)

Prins, K (author)

Strand, V (author)

Keystone, EC (author)

van Vollenhoven, RF (author)

Wollenhaupt, J (author)

Wartenberg-Demand, A (author)

Niemann, G (author)

Abufarag, A (author)

Aigner, S (author)

Kaiser, S (author)

Rharbaoui, F (author)

Czeloth, N (author)

Wolter, R (author)

Dalken, B (author)

Holzkamper, T (author)

show less...

2013

2013

English.

In: ARTHRITIS AND RHEUMATISM. - 0004-3591. ; 65, s. S596-S596

Related links:

http://kipublication...

• Conference paper (other academic/artistic)